Clinical Trial Update: A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

Phase I safety lead-in followed by Phase II randomised study evaluating ONCOS-102 with pemetrexed/c cisplatin in unresectable malignant pleural mesothelioma; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• ONCOS-102
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Targovax Oy | Conditions: To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy | Phase 1, Phase 2 | Status: UNKNOWN